Keisuke Shirakura

Keisuke Shirakura

Auto-generated profile, based on publicly available information

Keisuke Shirakura

Affiliation Department of Vascular Cell Biology, Max Planck Institute for Molecular Biomedicine, Münster, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2022 in Science Advances
Verified
Journal Article
Open access
RHRina Hashimoto
Rina Hashimoto
JTJunya Takahashi
Junya Takahashi
KSKeisuke Shirakura
Keisuke Shirakura
RFRisa Funatsu
Risa Funatsu
KKKaori Kosugi
Kaori Kosugi
YOYoshiaki Okada
Yoshiaki Okada
In the initial process of coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects respiratory epithelial cells and then transfers to other organs the blood vessels. It is believed that SARS-CoV-2 can pass the vascular wall by altering the endothelial barrier using an unknown mechanism. In this study, we investigated the effect of SARS-CoV-2 on the endothelial barrier using an airway-on-a-chip that mimics respiratory organs and found that SARS-CoV-2 produced from infected epithelial cells disrupts the barrier by decreasing Claudin-5 (CLDN5), a tight junction protein, and disrupting vascular endothelial cadherin–mediated adherens junctions. Consistently, the gene and protein expression levels of CLDN5 in the lungs of a patient with COVID-19 were decreased. CLDN5 overexpression or Fluvastatin treatment rescued the SARS-CoV-2–induced respiratory endothelial barrier disruption. We concluded that the down-regulation of CLDN5 expression is a pivotal mechanism for SARS-CoV-2–induced endothelial barrier disruption in respiratory organs and that inducing CLDN5 expression is a therapeutic strategy against COVID-19.

1 November 2017 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
YHYosuke Hashimoto
Yosuke Hashimoto
KSKeisuke Shirakura
Keisuke Shirakura
YOYoshiaki Okada
Yoshiaki Okada
HTHiroyuki Takeda
Hiroyuki Takeda
KEKohki Endo
Kohki Endo
MKMasuo Kondoh
Masuo Kondoh
A current bottleneck in the development of central nervous system (CNS) drugs is the lack of drug delivery systems targeting the CNS. The intercellular space between endothelial cells of the blood brain barrier (BBB) is sealed by complex protein-based structures called tight junctions (TJs). Claudin-5, a tetra-transmembrane protein is a key component of the TJ seal that prevents the paracellular diffusion of drugs into the CNS. In the present study, to investigate whether CLDN-5 binders can be used for delivery of drugs to the CNS, we generated monoclonal antibodies specific to the extracellular domains of CLDN-5. In an in vitro model of the blood-brain barrier, the anti-CLDN-5 mAbs dose-dependently attenuated TEER and enhanced solute permeation. These anti-CLDN-5 monoclonal antibodies are potential leads for the development of novel drug delivery systems targeting the CNS.

6 February 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
KSKeisuke Shirakura
Keisuke Shirakura
PBPeter Baluk
Peter Baluk
ANAstrid F Nottebaum
Astrid F Nottebaum
UIUte Ipe
Ute Ipe
KPKevin G Peters
Kevin G Peters
DVDietmar Vestweber
Dietmar Vestweber
Vascular endothelial protein tyrosine phosphatase (VE‐PTP) influences endothelial barrier function by regulating the activation of tyrosine kinase receptor Tie2. We determined whether this action is linked to the development of atherosclerosis by examining the influence of arterial shear stress on VE‐PTP, Tie2 activation, plasma leakage, and atherogenesis. We found that exposure to high average shear stress led to downstream polarization and endocytosis of VE‐PTP accompanied by Tie2 activation at cell junctions. In aortic regions with disturbed flow, VE‐PTP was not redistributed away from Tie2. Endothelial cells exposed to high shear stress had greater Tie2 activation and less macromolecular permeability than regions with disturbed flow. Deleting endothelial VE‐PTP in VE‐PTP iECKO mice increased Tie2 activation and reduced plasma leakage in atheroprone regions. ApoE −/− mice bred with VE‐PTP iECKO mice had less plasma leakage and fewer atheromas on a high‐fat diet. Pharmacologic inhibition of VE‐PTP by AKB‐9785 had similar anti‐atherogenic effects. Together, the findings identify VE‐PTP as a novel target for suppression of atherosclerosis.

30 May 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YHYosuke Hashimoto
Yosuke Hashimoto
WZWei Zhou
Wei Zhou
KHKohtaroh Hamauchi
Kohtaroh Hamauchi
KSKeisuke Shirakura
Keisuke Shirakura
TDTakefumi Doi
Takefumi Doi
HTHiroyuki Takeda
Hiroyuki Takeda
The production of antibodies against the extracellular regions (ECR) of multispanning membrane proteins is notoriously difficult because of the low productivity and immunogenicity of membrane proteins due to their complex structure and highly conserved sequences among species. Here, we introduce a new method to generate ECR-binding antibodies utilizing engineered liposomal immunogen prepared using a wheat cell-free protein synthesis system. We used claudin-5 (CLDN-5) as the target antigen, which is a notoriously difficult to produce and poorly immunogenic membrane protein with two highly conserved extracellular loops. We drastically improved the productivity of CLDN-5 in the cell-free system after suppressing and normalizing mRNA GC content. To overcome its low immunogenicity, two engineered antigens were designed and synthesized as proteoliposomes: a human/mouse chimeric CLDN-5, and a CLDN-5-based artificial membrane protein consisting of symmetrically arranged ECRs. Intraperitoneal immunization of both engineered CLDN-5 ECR antigens induced ECR-binding antibodies in mice with a high success rate. We isolated five monoclonal antibodies that specifically recognized CLDN-5 ECR. Antibody clone 2B12 showed high affinity (<10 nM) and inhibited CLDN-5-containing tight junctions. These results demonstrate the effectiveness of the methods for monoclonal antibody development targeting difficult-to-produce membrane proteins such as CLDNs.

12 January 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MMMaaya Morita
Maaya Morita
AYAki Yoneda
Aki Yoneda
NTNagisa Tokunoh
Nagisa Tokunoh
TMTatsumi Masaki
Tatsumi Masaki
KSKeisuke Shirakura
Keisuke Shirakura
YOYoshiaki Okada
Yoshiaki Okada
There is an urgent need to develop novel drugs to reduce the mortality from severe infectious diseases with the emergence of new pathogens, including Coronavirus disease 2019 (COVID-19). Although current drugs effectively suppress the proliferation of pathogens, immune cell activation, and inflammatory cytokine functions, they cannot completely reduce mortality from severe infections and sepsis. In this study, we focused on the endothelial cell-specific protein, Roundabout 4 (Robo4), which suppresses vascular permeability by stabilizing endothelial cells, and investigated whether enhanced Robo4 expression could be a novel therapeutic strategy against severe infectious diseases. Endothelial-specific overexpression of Robo4 suppresses vascular permeability and reduces mortality in lipopolysaccharide (LPS)-treated mice. Screening of small molecules that regulate Robo4 expression and subsequent analysis revealed that two competitive small mothers against decapentaplegic (SMAD) signaling pathways, activin receptor-like kinase 5 (ALK5)-SMAD2/3 and ALK1-SMAD1/5, positively and negatively regulate Robo4 expression, respectively. An ALK1 inhibitor was found to increase Robo4 expression in mouse lungs, suppress vascular permeability, prevent extravasation of melanoma cells, and decrease mortality in LPS-treated mice. The inhibitor suppressed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced endothelial barrier disruption and decreased mortality in mice infected with SARS-CoV-2. These results indicate that enhancing Robo4 expression is an efficient strategy to suppress vascular permeability and mortality in severe infectious diseases, including COVID-19, and that small molecules that upregulate Robo4 can be potential therapeutic agents against these diseases.

4 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TTToru Tanaka
Toru Tanaka
KIKohei Izawa
Kohei Izawa
YMYusuke Maniwa
Yusuke Maniwa
MOMaki Okamura
Maki Okamura
AOAtsumasa Okada
Atsumasa Okada
YOYoshiaki Okada
Yoshiaki Okada
Although transcription factors regulating endothelial cell (EC)-specific gene expression have been identified, it is not known how those factors induce EC-specificity. We previously reported that DNA hypomethylation of the proximal promoter elicits EC-specific expression of Roundabout4 (Robo4). However, the mechanisms establishing EC-specific hypomethylation of the Robo4 promoter remain unknown. In this study, we demonstrated that the hypermethylated Robo4 proximal promoter is demethylated as human iPS cells differentiate into endothelial cells. Reporter assays demonstrated that ETV2, an ETS family transcription factor, bound to ETS motifs in the proximal promoter and activated Robo4 expression. Immunoprecipitation demonstrated direct interaction between ETV2 and methylcytosine-converting enzymes TET1 and TET2. Adenoviral expression of ETV2-TET1/TET2 complexes demethylated the Robo4 promoter and induced Robo4 expression in non-ECs. In summary, we propose a novel regulatory model of EC-specific gene expression via promoter demethylation induced by ETV2-TET1/TET2 complexes during endothelial differentiation.